MP09-03 combination therapy of tadalafil and tamsulosin for MEN with moderate to severe benign prostatic hyperplasia
Abstract
You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Non-surgical Therapy1 Apr 2017MP09-03 COMBINATION THERAPY OF TADALAFIL AND TAMSULOSIN FOR MEN WITH MODERATE TO SEVERE BENIGN PROSTATIC HYPERPLASIA Hyun Jun Park, Tae Nam Kim, Jong Kil Nam, Du Geon Moon, and Nam Cheol Park Hyun Jun ParkHyun Jun Park More articles by this author , Tae Nam KimTae Nam Kim More articles by this author , Jong Kil NamJong Kil Nam More articles by this author , Du Geon MoonDu Geon Moon More articles by this author , and Nam Cheol ParkNam Cheol Park More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.311AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Benign prostatic hyperplasia (BPH) is commonly treated with alpha-blockers and 5-alpha-reductase inhibitors (5ARIs). However, tamsulosin has sexual side-effects, including ejaculatory dysfunction. Recently, tadalafil 5 mg daily has been shown to be helpful in treating lower urinary tract symptoms (LUTS). Thus, we compared tadalafil and tamsulosin with tamsulosin alone in terms of symptom improvement in males with moderate to severe BPH. METHODS This 12-week study was a randomized, parallel group evaluation of clinical outcomes in males aged ≥ 50 years with symptomatic (IPSS≥12) BPH and a prostate volume ≥ 30 mL. Eligible patients received a combination of tadalafil 5 mg daily with tamsulosin…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 30 participants or records.
Read the paper
Related studies
- Erectile dysfunction
- Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit
- Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
- Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets
- Chronic bladder ischemia and oxidative stress: New pharmacotherapeutic targets for lower urinary tract symptoms
- The role of prostate inflammation and fibrosis in lower urinary tract symptoms
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.